Sex-related gap found for use of DMTs in MS patients ages 18-40
Despite evidence supporting the safety of disease-modifying therapies (DMTs) during pregnancy, women with multiple sclerosis (MS) in their childbearing years are significantly less likely than men in the same age range to receive these typically most effective treatments, according to a study from France. The researchers found what they…